

## NCCN Ovarian Cancer V.1.2011 – Update Teleconference – June 1, 2010

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><u>OV-E</u> Internal request: Institutional review comment requesting the addition of nab-paclitaxel (albumin bound) to “other potentially active agents” for recurrent ovarian cancer/fallopian tube cancer/primary peritoneal cancer.</p>	<p>Based on data from the referenced study, the Panel added nab-paclitaxel (albumin bound) as an acceptable recurrence therapy.</p>	<p>Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009;27:1426-1431. Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/19224848">http://www.ncbi.nlm.nih.gov/pubmed/19224848</a></p>	15	0	0
<p><u>OV-E</u> Internal request: Institutional review comment to list pemetrexed under “other potentially active agents” for recurrent ovarian cancer/fallopian tube cancer/primary peritoneal cancer.</p>	<p>The Panel moved pemetrexed from a preferred agent to the list of other potentially active agents for recurrent ovarian cancer/fallopian tube cancer/primary peritoneal cancer.</p>		15	0	0

## NCCN Ovarian Cancer V.1.2011 – Update Teleconference – June 1, 2010

<p><a href="#">LCOH-A</a> Internal request: Institutional review comment requesting aromatase inhibitors be added as “acceptable recurrence therapies” for sex cord-stromal tumors.</p>	<p>Based on the references listed, the aromatase inhibitors anastrozole and letrozole were added as acceptable recurrence therapies for sex cord-stromal tumors.</p>	<p>Papadimitriou CA, Markaki S, Siapkarakas J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. <i>Oncology</i> 2004;66:112-Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/15138362">http://www.ncbi.nlm.nih.gov/pubmed/15138362</a> del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. <i>Gynecol Oncol</i> 2003;91:596-602. Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/14675683">http://www.ncbi.nlm.nih.gov/pubmed/14675683</a> Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. <i>Gynecol Oncol</i> 2008;110:56-59. Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/18457865">http://www.ncbi.nlm.nih.gov/pubmed/18457865</a></p>	<p>15</p>	<p>0</p>	
---	--	---	-----------	----------	--